Regeneron Pharmaceuticals
REGN
719 hedge funds and large institutions have $30.4B invested in Regeneron Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 116 funds opening new positions, 308 increasing their positions, 189 reducing their positions, and 62 closing their positions.
87% more first-time investments, than exits
New positions opened: 116 | Existing positions closed: 62
63% more repeat investments, than reductions
Existing positions increased: 308 | Existing positions reduced: 189
11% more capital invested
Capital invested by funds: $27.4B → $30.4B (+$3.01B)
7% more funds holding
Funds holding: 671 → 719 (+48)
0.01% more ownership
Funds ownership: 68.96% → 68.97% (+0.01%)
27% less funds holding in top 10
Funds holding in top 10: 15 → 11 (-4)
36% less call options, than puts
Call options by funds: $509M | Put options by funds: $791M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$456M |
| 2 |
JP Morgan Chase
New York
|
+$427M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$190M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$96.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$79.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$381M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$367M |
| 3 |
ClearBridge Investments
New York
|
-$313M |
| 4 |
Janus Henderson Group
London,
|
-$208M |
| 5 |
HM
HealthCor Management
New York
|
-$165M |
REGN Hedge Fund Activity: Q1 2019 in Review
719 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2019, worth a combined $30.4B — up 11% from $27.4B a quarter earlier.
Buyers outnumbered sellers: 116 funds opened new REGN positions and 62 closed out — a net gain of 54 holders — while 308 added to existing stakes and 189 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $456M. The largest seller was Fidelity Investments, cutting an estimated $381M.
- 719 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2019, up from 671 in Q4 2018.
- Funds reported $30.4B of Regeneron Pharmaceuticals stock for Q1 2019, up 11% quarter-over-quarter.
- 116 funds opened new Regeneron Pharmaceuticals positions in Q1 2019 and 62 closed out, a net change of +54 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2019 was T. Rowe Price Associates, an estimated $456M added.
- The largest Regeneron Pharmaceuticals seller in Q1 2019 was Fidelity Investments, an estimated $381M sold.
Based on aggregated 13F filings for Q1 2019.